Sichuan Qingmu Pharmaceutical is a Pharmaceutical company, Veterinary Company, CMO/CDMO, Generics/Biosimilars Manufacturer company operating in the pharmaceutical industry.
Qingmu Pharmaceutical was founded in May 2011, is a wholly-owned subsidiary of Easton Biopharmaceuticals (Stock code: 688513). Qingmu is an innovation driven pharmaceutical company with primary strategic focus on the regulated market, the company specialized in R&D and manufacturing of generic APIs and advanced intermediates, and also provides CDMO/CMO service for small molecule chemical drugs. Qingmu was inspected and approved by US FDA, Korean MFDS and Chinese NMPA
Company type
Pharmaceutical company, Veterinary Company, CMO/CDMO, Generics/Biosimilars Manufacturer
Products and services
APIs (Active Pharmaceutical Ingredients)
Markets
North America (USA, Canada), Africa, Middle East Region (e.g. UAE), Central America (e.g. Mexico), East Asia (e.g. China, Japan, Korea), Europe – EU countries, Europe – non EU (e.g. UK, Russia, ex-CIS countries), South America (e.g. Brazil, Colombia), South Asia (e.g. India, Pakistan, Sri Lanka)
Address
Sichuan Qingmu Pharmaceutical, No.55, South Shunjiang Avenue, East Economic, Chengdu, China, 612100
